Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay

The current number of drugs available for the treatment of Alzheimer’s disease (AD) is strongly limited and their benefit for therapy is given only in the early state of the disease. An effective therapy should affect those processes which mainly contribute to the neuronal decay. There have been man...

Descripción completa

Detalles Bibliográficos
Autores principales: Holzer, Max, Schade, Nico, Opitz, Ansgar, Hilbrich, Isabel, Stieler, Jens, Vogel, Tim, Neukel, Valentina, Oberstadt, Moritz, Totzke, Frank, Schächtele, Christoph, Sippl, Wolfgang, Hilgeroth, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225193/
https://www.ncbi.nlm.nih.gov/pubmed/30213139
http://dx.doi.org/10.3390/molecules23092335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225193/
https://www.ncbi.nlm.nih.gov/pubmed/30213139
http://dx.doi.org/10.3390/molecules23092335

Ejemplares similares